^
    1d
    OPTIMUS-EL: Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy (clinicaltrials.gov)
    P2, N=40, Recruiting, Seoul National University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Elrexfio (elranatamab-bcmm)
    2d
    Trilogy-4: A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, Janssen Research & Development, LLC
    New P3 trial
    |
    JNJ-5322 • Tecvayli (teclistamab-cqyv)
    9d
    ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma (clinicaltrials.gov)
    P2, N=160, Not yet recruiting, Massachusetts General Hospital
    New P2 trial
    |
    clonoSEQ
    |
    lenalidomide • bortezomib • Elrexfio (elranatamab-bcmm) • Darzalex Faspro (daratumumab and hyaluronidase-fihj) • dexamethasone injection
    10d
    MajesTEC-9: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P3, N=614, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • carfilzomib • pomalidomide • Tecvayli (teclistamab-cqyv)
    15d
    Absolute Bioavailability Study of Cizutamig in Healthy Adult Participants (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Candid Therapeutics
    New P1 trial
    17d
    Clinical Study of Cizutamig in Systemic Lupus Erythematosus (clinicaltrials.gov)
    P1, N=47, Recruiting, Candid Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    17d
    Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG) (clinicaltrials.gov)
    P1, N=44, Recruiting, Candid Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    21d
    OM336 in Seropositive Autoimmune Diseases (clinicaltrials.gov)
    P1, N=39, Not yet recruiting, Ouro Medicines
    New P1 trial
    22d
    A Study to Assess Adverse Events of Intravenously (IV) Infused ABBV-383 in Adult Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=180, Recruiting, AbbVie | Trial completion date: Mar 2027 --> Aug 2029 | Trial primary completion date: Mar 2027 --> Aug 2029
    Trial completion date • Trial primary completion date • Adverse events
    |
    etentamig intravenous (ABBV-383 IV)
    26d
    Cytomegalovirus reactivation with severe lymphopenia during elranatamab treatment: a case series in patients with triple-class refractory multiple myeloma. (PubMed, J Infect Chemother)
    All reactivation cases were detected by PCR (>500 IU/mL) and managed pre-emptively with valganciclovir; no CMV disease occurred. Further prospective studies are warranted to optimize infection surveillance and prophylactic strategies in this population. To our knowledge, this is the first case series from Japan to describe infectious complications of ELRA in routine practice, providing important real-world evidence for clinicians.
    Journal
    |
    CD4 (CD4 Molecule)
    |
    Elrexfio (elranatamab-bcmm) • Valcyte (valganciclovir)
    29d
    MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, University of Arkansas | Initiation date: Oct 2025 --> Apr 2026
    Trial initiation date
    |
    clonoSEQ
    |
    lenalidomide • Darzalex (daratumumab) • melphalan • Talvey (talquetamab-tgvs) • Tecvayli (teclistamab-cqyv)
    1m
    Study to evaluate Cizutamig in patients with immunoglobulin A nephropathy (ChiCTR2500107535)
    P=N/A, N=15, Recruiting, Peking University First Hospital; Peking University First Hospital
    New trial